Hendrik Nogai

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors.

A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors.

Journal: Targeted oncology
Published: May 11, 2025

Patient Selection Approaches in FGFR Inhibitor Trials-Many Paths to the Same End?

Patient Selection Approaches in FGFR Inhibitor Trials-Many Paths to the Same End?

Journal: Cells
Published: September 14, 2022

Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib.

Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib.

Journal: Cancer genetics
Published: August 11, 2021

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.

Journal: The Lancet. Oncology
Published: April 12, 2019

Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.

Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 15, 2017

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.

Journal: British journal of cancer
Published: September 12, 2016

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.

Journal: Biomarker insights
Published: April 28, 2015

Neurocognitive function, brain-derived neurotrophic factor (BDNF) and IL-6 levels in cancer patients with depression.

Neurocognitive function, brain-derived neurotrophic factor (BDNF) and IL-6 levels in cancer patients with depression.

Journal: Journal of neuroimmunology
Published: March 15, 2015

Synchronous tuberculosis, Epstein-Barr virus-associated lymphoproliferative disorder and cytomegalovirus infection in an allogeneic transplant recipient: a case report.

Synchronous tuberculosis, Epstein-Barr virus-associated lymphoproliferative disorder and cytomegalovirus infection in an allogeneic transplant recipient: a case report.

Journal: SpringerPlus
Published: December 13, 2013

IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL.

IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL.

Journal: Blood
Published: July 23, 2013

PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.

PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 11, 2013

Improvement of paraneoplastic limbic encephalitis after systemic treatment with rituximab in a patient with B-cell chronic lymphocytic leukemia.

Improvement of paraneoplastic limbic encephalitis after systemic treatment with rituximab in a patient with B-cell chronic lymphocytic leukemia.

Journal: Case reports in hematology
Published: May 29, 2013
Showing 1-12 of 12

Last Updated: 09/26/2026